Literature DB >> 27154787

The need for preoperative baseline arm measurement to accurately quantify breast cancer-related lymphedema.

Fangdi Sun1, Melissa N Skolny1, Meyha N Swaroop1, Bhupendra Rawal2, Paul J Catalano2, Cheryl L Brunelle3, Cynthia L Miller1, Alphonse G Taghian4.   

Abstract

Breast cancer-related lymphedema (BCRL) is a feared outcome of breast cancer treatment, yet the push for early screening is hampered by a lack of standardized quantification. We sought to determine the necessity of preoperative baseline in accounting for temporal changes of upper extremity volume. 1028 women with unilateral breast cancer were prospectively screened for lymphedema by perometry. Thresholds were defined: relative volume change (RVC) ≥10 % for clinically significant lymphedema and ≥5 % including subclinical lymphedema. The first postoperative measurement (pseudo-baseline) simulated the case of no baseline. McNemar's test and binomial logistic regression models were used to analyze BCRL misdiagnoses. Preoperatively, 28.3 and 2.9 % of patients had arm asymmetry of ≥5 and 10 %, respectively. Without baseline, 41.6 % of patients were underdiagnosed and 40.1 % overdiagnosed at RVC ≥ 5 %, increasing to 50.0 and 54.8 % at RVC ≥ 10 %. Increased pseudo-baseline asymmetry, increased weight change between baselines, hormonal therapy, dominant use of contralateral arm, and not receiving axillary lymph node dissection (ALND) were associated with increased risk of underdiagnosis at RVC ≥ 5 %; not receiving regional lymph node radiation was significant at RVC ≥ 10 %. Increased pseudo-baseline asymmetry, not receiving ALND, and dominant use of ipsilateral arm were associated with overdiagnosis at RVC ≥ 5 %; increased pseudo-baseline asymmetry and not receiving ALND were significant at RVC ≥ 10 %. The use of a postoperative proxy even early after treatment results in poor sensitivity for identifying BCRL. Providers with access to patients before surgery should consider the consequent need for proper baseline, with specific strategy tailored by institution.

Entities:  

Keywords:  Breast cancer; Lymphedema; Quantification; Standardization; Temporal baseline; Treatment morbidity

Mesh:

Year:  2016        PMID: 27154787     DOI: 10.1007/s10549-016-3821-0

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  17 in total

1.  Timing of Lymphedema After Treatment for Breast Cancer: When Are Patients Most At Risk?

Authors:  Susan G R McDuff; Amir I Mina; Cheryl L Brunelle; Laura Salama; Laura E G Warren; Mohamed Abouegylah; Meyha Swaroop; Melissa N Skolny; Maria Asdourian; Tessa Gillespie; Kayla Daniell; Hoda E Sayegh; George E Naoum; Hui Zheng; Alphonse G Taghian
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-08-28       Impact factor: 7.038

2.  Patients who report cording after breast cancer surgery are at higher risk of lymphedema: Results from a large prospective screening cohort.

Authors:  Cheryl L Brunelle; Sacha A Roberts; Amy M Shui; Tessa C Gillespie; Kayla M Daniell; George E Naoum; Alphonse Taghian
Journal:  J Surg Oncol       Date:  2020-06-04       Impact factor: 3.454

3.  Perometry versus simulated circumferential tape measurement for the detection of breast cancer-related lymphedema.

Authors:  Fangdi Sun; Alexander Hall; Megan P Tighe; Cheryl L Brunelle; Hoda E Sayegh; Tessa C Gillespie; Kayla M Daniell; Alphonse G Taghian
Journal:  Breast Cancer Res Treat       Date:  2018-07-30       Impact factor: 4.872

4.  Hand Edema in Patients at Risk of Breast Cancer-Related Lymphedema: Health Professionals Should Take Notice.

Authors:  Cheryl L Brunelle; Meyha N Swaroop; Melissa N Skolny; Maria S Asdourian; Hoda E Sayegh; Alphonse G Taghian
Journal:  Phys Ther       Date:  2018-06-01

Review 5.  Breast Cancer-Related Lymphedema: Risk Factors, Screening, Management, and the Impact of Locoregional Treatment.

Authors:  Sarah A McLaughlin; Cheryl L Brunelle; Alphonse Taghian
Journal:  J Clin Oncol       Date:  2020-05-22       Impact factor: 44.544

Review 6.  Breast cancer-related lymphedema: risk factors, precautionary measures, and treatments.

Authors:  Tessa C Gillespie; Hoda E Sayegh; Cheryl L Brunelle; Kayla M Daniell; Alphonse G Taghian
Journal:  Gland Surg       Date:  2018-08

Review 7.  Use of technology to facilitate a prospective surveillance program for breast cancer-related lymphedema at the Massachusetts General Hospital.

Authors:  Lauren M Havens; Cheryl L Brunelle; Tessa C Gillespie; Madison Bernstein; Loryn K Bucci; Yara W Kassamani; Alphonse G Taghian
Journal:  Mhealth       Date:  2021-01-20

8.  Subclinical Lymphedema After Treatment for Breast Cancer: Risk of Progression and Considerations for Early Intervention.

Authors:  Loryn K Bucci; Cheryl L Brunelle; Madison C Bernstein; Amy M Shui; Tessa C Gillespie; Sacha A Roberts; George E Naoum; Alphonse G Taghian
Journal:  Ann Surg Oncol       Date:  2021-06-11       Impact factor: 5.344

9.  Diagnostic Methods, Risk Factors, Prevention, and Management of Breast Cancer-Related Lymphedema: Past, Present, and Future Directions.

Authors:  Hoda E Sayegh; Maria S Asdourian; Meyha N Swaroop; Cheryl L Brunelle; Melissa N Skolny; Laura Salama; Alphonse G Taghian
Journal:  Curr Breast Cancer Rep       Date:  2017-05-03

10.  The legacy of lymphedema: Impact on nursing practice and vascular access.

Authors:  Gail Larocque; Sheryl McDiarmid
Journal:  Can Oncol Nurs J       Date:  2019-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.